Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2022

“Muscarinic Acetylcholine Receptor M1 Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Muscarinic Acetylcholine Receptor M1 Antagonists Understanding

Muscarinic Acetylcholine Receptor M1 Antagonists: Overview

The mAChRs are a sub-class of the G-protein-coupled receptors (GPCRs) family, comprising 5 subtypes (M1-M5). M1, M3, and M5 are coupled with the Gq protein and, via phospholipase C signaling pathway, generate cytosolic calcium transients; M2 and M4, on the other hand, couple with the Gi protein inhibiting the adenylyl cyclase. While obtaining mAChRs subtype-selective ligands is a primary goal in drug development previous attempts have failed due to the highly conserved structure of the orthosteric binding site across the muscarinic receptor family members.

Muscarinic Acetylcholine Receptor M1 Antagonists Emerging Drugs Chapters

This segment of the Muscarinic Acetylcholine Receptor M1 Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Muscarinic Acetylcholine Receptor M1 Antagonists Emerging Drugs
• KarXT - Karuna Therapeutics

Karuna Therapeutics lead product candidate, KarXT, selectively activates muscarinic acetylcholine receptors in the brain to unlock the therapeutic potential of xanomeline, which previously demonstrated significant benefits in Phase 2 studies in schizophrenia and Alzheimer’s.

Further product details are provided in the report……..

Muscarinic Acetylcholine Receptor M1 Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Muscarinic Acetylcholine Receptor M1 Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Muscarinic Acetylcholine Receptor M1 Antagonists

There are approx. 20+ key companies which are developing the Muscarinic Acetylcholine Receptor M1 Antagonists. The companies which have their Muscarinic Acetylcholine Receptor M1 Antagonists drug candidates in the most advanced stage, i.e. phase II include, Karuna Therapeutics.
• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Muscarinic Acetylcholine Receptor M1 Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Muscarinic Acetylcholine Receptor M1 Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscarinic Acetylcholine Receptor M1 Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscarinic Acetylcholine Receptor M1 Antagonists drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Muscarinic Acetylcholine Receptor M1 Antagonists R&D. The therapies under development are focused on novel approaches for Muscarinic Acetylcholine Receptor M1 Antagonists.

Muscarinic Acetylcholine Receptor M1 Antagonists Report Insights
• Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Muscarinic Acetylcholine Receptor M1 Antagonists Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Muscarinic Acetylcholine Receptor M1 Antagonists drugs?
• How many Muscarinic Acetylcholine Receptor M1 Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Muscarinic Acetylcholine Receptor M1 Antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Muscarinic Acetylcholine Receptor M1 Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Muscarinic Acetylcholine Receptor M1 Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Karuna Therapeutics

Key Products
• KarXT